Shares of Pier 1 Imports, Inc. (NYSE:PIR) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease of -2.82% to close at $3.96. Pier 1 Imports (PIR) stated that now it expects loss in its q2 as compared to previous view among loss and breakeven. The firm also revealed the planned departure of its Chief Executive Officer Alex Smith.
In its q2, net sales reduced about 6.7% compared to the same period a year ago. E-Commerce sales represented about 20% of net sales. Firm same sales, which include e-Commerce, reduced about 4.3%. For the quarter, the firm now expects loss per share to be in the range of $0.06 to $0.05, not comprising one-time items, if any, related to the departure of CEO. The firm before predictable to report loss of $0.06 per share to breakeven. On average, 18 analysts polled by Thomson Reuters expect loss of $0.03 per share for the quarter. Analysts’ anticipates typically exclude special items. Moving forward to saw long-term intention, the experts calculate Return on Investment of 10.60%. The stock is going forward its fifty-two week low with 8.08% and lagging behind from its 52-week high price with -59.80%. PIR last month stock price volatility remained 4.09%.
Viveve Medical, Inc. (NASDAQ:VIVE) [Trend Analysis] retains strong position in active trade, as shares scoring 6.26% to $8.49 in a active trade session, while looking at the shares volume, about 729 shares have changed hands in this session. Viveve Medical, Inc. (VIVE) reported that the Firm has attained regulatory authorization for the sale of Viveve System from the Therapeutic Goods Administration (TGA) in Australia. The Firm also reported a new distribution alliance for the Viveve System in Australia and New Zealand with Device Consulting, a distinguished supplier of medical products headquartered in Victoria, Australia.
The chief executive officer of Viveve, Patricia Scheller stated that their regulatory authorization in Australia and their distribution alliance with Device Consulting represent important milestones in their rapidly expanding efforts to build a global commercial infrastructure for the Viveve System. “Our research shows that vaginal laxity is a important risk and concern for women following pregnancy. We believe that the clinically demonstrated safety and efficacy profile of this painless procedure will position the Viveve Treatment as the best alternative for a condition that can profoundly impact a woman’s sexual satisfaction and quality of life. We look forward to bringing the advantages of the Viveve System to women in this region who are living with the challenges of vaginal laxity.” VIVE attains analyst recommendation of 2.00 with week’s performance of -11.22%. Investors looking additional ahead will note that the Price to next year’s EPS is 29.10%.